| Synonym |
| Thai / English name |
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 14*N(Treatment) : 7**Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : Voriconazole 200 mg after administration of Ginkgo biloba 120 mg twice daily.Duration : 12 daysType of interaction : PharmacokineticsInteraction with drug : VoriconazoleDose/Conc.(drug) : -Result : EquivocalRemark : * Healthy and nonsmoking volunteers. ** CYP2C19 poor metabolizers (2C19*2/2C19*2). Results: Pharmacokinetic parameters of voriconazole for poor metabolizers were similar pattern of extensive metabolizers.Note : - 2 phase randomized crossover study with 4 weeks washout between phases. - Data incomplete.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Ginkgo biloba extract (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10N(Treatment) : 10Sex : MaleAge : 21-27 yearsRoute : Oral administrationDose/Conc.(herb) : Talinolol 100 mg with a single oral dose of GBE 120 mgDuration : 24 hoursType of interaction : PharmacokineticsInteraction with drug : TalinololDose/Conc.(drug) : -Result : NegativeRemark : Result: A single oral dose of GBE did not affect the pharmacokinetics of talinolol. Primary constituents of ginkgo include flavonoids were reported to be substrates and modulators of P-glycoprotein. Further studies are required to identify whether quercetin and kaempferol are active substances in GBE to inhibit P-glycoprotein in humans.Note : - The pharmacokinetics of oral talinolol were determined after administration of a 100 mg tablet of talinolol at 24 hours in a 3-stage sequential study. The first tablet of talinolol was given on day 1 of the study. The second tablet was taken on day 8 with a single oral dose of a GBE 120 mg tablet. On days 9 through 22, same dose of a GBE was ingested by each subject 3 time daily. The final tablet of talinolol was taken on day 23, wtih 44th dose of GBE. - Healthy subjects.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Ginkgo biloba extract (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10N(Treatment) : 10Sex : MaleAge : 21-27 yearsRoute : Oral administrationDose/Conc.(herb) : Talinolol 100 mg with a single oral dose of GBE 120 mgDuration : 24 hoursType of interaction : PharmacokineticsInteraction with drug : TalinololDose/Conc.(drug) : -Result : NegativeRemark : Result: Repeated ingestion of GBE increased the talinolol maximum plasma concentration(C max) by 36% (90% Cl 10-68; p=0.025), the area under the concentration-time curve (AUC)0-24-by 26% (90% CL 11-43; p=0.008) and AUC0-infinity by 22% (90% Cl 8-37; p=0.014), respectively, without significant changes in elimination half-life and the tin to Cmax.Note : - The pharmacokinetics of oral talinolol were determined after administration of a 100 mg tablet of talinolol at 24 hours in a 3-stage sequential study. The first tablet of talinolol was given on day 1 of the study. The second tablet was taken on day 8 with a single oral dose of a GBE 120 mg tablet. On days 9 through 22, same dose of a GBE was ingested by each subject 3 time daily. The final tablet of talinolol was taken on day 23, wtih 44th dose of GBE. - Healthy subjects.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : -Duration : 8 daysType of interaction : PharmacokineticsInteraction with drug : Phenytoin*/Diphenylhydantoin/DPHDose/Conc.(drug) : -Result : PositiveRemark : Ginkgo biloba pretreated rats increased the bioavailability of phenytoin by 2.08 fold when compared with control.Note : - Pretreatment 7 days with noni juice or Ginkgo biloba, on day 8 the phenytoin was co-administrered orally with noni juice or Ginkgo biloba and the serum pharmacokinetics were determined at various time options (1, 2, 4, 6, 8, 12 and 24 hours) by HPLC. - Data incomplete
